These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
406 related articles for article (PubMed ID: 30179848)
1. Current understanding and future directions in the application of TIMP-2 and IGFBP7 in AKI clinical practice. Fan W; Ankawi G; Zhang J; Digvijay K; Giavarina D; Yin Y; Ronco C Clin Chem Lab Med; 2019 Apr; 57(5):567-576. PubMed ID: 30179848 [TBL] [Abstract][Full Text] [Related]
2. Clinical Use of the Urine Biomarker [TIMP-2] × [IGFBP7] for Acute Kidney Injury Risk Assessment. Vijayan A; Faubel S; Askenazi DJ; Cerda J; Fissell WH; Heung M; Humphreys BD; Koyner JL; Liu KD; Mour G; Nolin TD; Bihorac A; Am J Kidney Dis; 2016 Jul; 68(1):19-28. PubMed ID: 26948834 [TBL] [Abstract][Full Text] [Related]
3. Early prediction of acute kidney injury after transapical and transaortic aortic valve implantation with urinary G1 cell cycle arrest biomarkers. Dusse F; Edayadiyil-Dudásova M; Thielmann M; Wendt D; Kahlert P; Demircioglu E; Jakob H; Schaefer ST; Pilarczyk K BMC Anesthesiol; 2016 Sep; 16():76. PubMed ID: 27609347 [TBL] [Abstract][Full Text] [Related]
4. Intraoperative prediction of cardiac surgery-associated acute kidney injury using urinary biomarkers of cell cycle arrest. Cummings JJ; Shaw AD; Shi J; Lopez MG; O'Neal JB; Billings FT J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1545-1553.e5. PubMed ID: 30389130 [TBL] [Abstract][Full Text] [Related]
5. Urinary biomarkers TIMP-2 and IGFBP7 early predict acute kidney injury after major surgery. Gocze I; Koch M; Renner P; Zeman F; Graf BM; Dahlke MH; Nerlich M; Schlitt HJ; Kellum JA; Bein T PLoS One; 2015; 10(3):e0120863. PubMed ID: 25798585 [TBL] [Abstract][Full Text] [Related]
9. Association of Renal Stress/Damage and Filtration Biomarkers with Subsequent AKI during Hospitalization among Patients Presenting to the Emergency Department. Kimmel M; Shi J; Latus J; Wasser C; Kitterer D; Braun N; Alscher MD Clin J Am Soc Nephrol; 2016 Jun; 11(6):938-946. PubMed ID: 27026519 [TBL] [Abstract][Full Text] [Related]
10. Cisplatin nephrotoxicity is not detected by urinary cell-cycle arrest biomarkers in lung cancer patients. Toprak Z; Cebeci E; Helvaci SA; Toprak ID; Kutlu Y; Sakin A; Tukek T Int Urol Nephrol; 2017 Jun; 49(6):1041-1047. PubMed ID: 28255639 [TBL] [Abstract][Full Text] [Related]
11. Assessment of cell-cycle arrest biomarkers to predict early and delayed acute kidney injury. Bell M; Larsson A; Venge P; Bellomo R; Mårtensson J Dis Markers; 2015; 2015():158658. PubMed ID: 25866432 [TBL] [Abstract][Full Text] [Related]
12. Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. Meersch M; Schmidt C; Van Aken H; Martens S; Rossaint J; Singbartl K; Görlich D; Kellum JA; Zarbock A PLoS One; 2014; 9(3):e93460. PubMed ID: 24675717 [TBL] [Abstract][Full Text] [Related]
13. Urinary Biomarkers IGFBP7 and TIMP-2 for the Diagnostic Assessment of Transient and Persistent Acute Kidney Injury in Critically Ill Patients. Daubin D; Cristol JP; Dupuy AM; Kuster N; Besnard N; Platon L; Buzançais A; Brunot V; Garnier F; Jonquet O; Klouche K PLoS One; 2017; 12(1):e0169674. PubMed ID: 28085896 [TBL] [Abstract][Full Text] [Related]
15. Tissue inhibitor metalloproteinase-2 (TIMP-2) • IGF-binding protein-7 (IGFBP7) levels are associated with adverse outcomes in patients in the intensive care unit with acute kidney injury. Xie Y; Ankawi G; Yang B; Garzotto F; Passannante A; Breglia A; Digvijay K; Ferrari F; Brendolan A; Raffaele B; Giavarina D; Gregori D; Ronco C Kidney Int; 2019 Jun; 95(6):1486-1493. PubMed ID: 30982674 [TBL] [Abstract][Full Text] [Related]
16. Economic and clinical benefits of early identification of acute kidney injury using a urinary biomarker. Berdugo MA; Kirson NY; Zimmer L; Beyhaghi H; Toback S; Scarpati LM; Stone MN; Dember R; Tseng-Tham J; Wen J; Miller M J Med Econ; 2019 Dec; 22(12):1281-1289. PubMed ID: 31234668 [No Abstract] [Full Text] [Related]
17. Urinary [TIMP-2] × [IGFBP7] for risk prediction of acute kidney injury in decompensated heart failure. Schanz M; Shi J; Wasser C; Alscher MD; Kimmel M Clin Cardiol; 2017 Jul; 40(7):485-491. PubMed ID: 28295429 [TBL] [Abstract][Full Text] [Related]
18. Biomarker Rule-in or Rule-out in Patients With Acute Diseases for Validation of Acute Kidney Injury in the Emergency Department (BRAVA): A Multicenter Study Evaluating Urinary TIMP-2/IGFBP7. Yang HS; Hur M; Lee KR; Kim H; Kim HY; Kim JW; Chua MT; Kuan WS; Chua HR; Kitiyakara C; Phattharapornjaroen P; Chittamma A; Werayachankul T; Anandh U; Herath S; Endre Z; Horvath AR; Antonini P; Di Somma S; Ann Lab Med; 2022 Mar; 42(2):178-187. PubMed ID: 34635611 [TBL] [Abstract][Full Text] [Related]
19. Tissue Inhibitor Metalloproteinase-2 (TIMP-2)⋅IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI. Koyner JL; Shaw AD; Chawla LS; Hoste EA; Bihorac A; Kashani K; Haase M; Shi J; Kellum JA; J Am Soc Nephrol; 2015 Jul; 26(7):1747-54. PubMed ID: 25535301 [TBL] [Abstract][Full Text] [Related]
20. The role of biomarkers in early identification of acute kidney injury among non-critically ill patients. Safadi S; Hommos MS; Thongprayoon C; Giesen CD; Bernaba M; Kashani KB; Lieske JC J Nephrol; 2024 Jun; 37(5):1327-1338. PubMed ID: 38837000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]